-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sotorasib (LUMAKRAS®) developed by Amgen is a KRAS inhibitor that was approved by the US FDA for accelerated marketing on May 28, 2021 for the treatment of locally advanced or metastatic non-small cell lung cancer with KRASG12C mutation [1]
.
Sotorasib is currently the only targeted drug approved to market for the treatment of locally advanced or metastatic NSCLC patients with KRASG12C mutations.
It has been awarded the title of orphan drug and breakthrough therapy and priority review qualification
.
According to a statistics on KRASG12C mutations in Chinese non-small cell lung cancer patients, KRAS mutations are the second most common genetic mutation in Chinese non-small cell lung cancer (NSCLC) patients
.
About 10% of NSCLC patients carry KRAS mutations, of which nearly 30% are KRASG12C mutation subtypes (KRASG12C mutation is a biomarker of poor prognosis for Chinese non-small cell lung cancer patients), that is, the occurrence of KRASG12C mutations in Chinese non-small cell lung cancer patients The rate is close to 3%[2]
.
Sotorasib's approval is mainly based on a phase I/II clinical trial (NCT03600883)
.
Clinical results showed that among 124 patients with locally advanced or metastatic NSCLC who had disease progression after receiving immune checkpoint inhibitors and/or platinum-based chemotherapy, the objective response rate (ORR) of the Sotorasib group reached 36%, and the median response continued The duration was 10 months, and 58% of patients had a duration of remission (DOR) ≥ 6 months [3]
.
For details of Sotorasib and the competitive landscape of KRAS inhibitor chemicals, see the picture below: (click to enlarge to view) You can also click the link below to get the corresponding PDF HD version: https://data.
pharmacodia.
com/v3/insight/#/ListPdf? tag=2Yaodu APP "points new gameplay" company enjoys the database of super-valued medicines intestinal-hepatic circulation in the human body: The influence of BCS classification on the solubility, permeability and dissolution of APIs May 2021 China CDE Drugs Click "Read the original text" for the declaration status to keep abreast of industry trends
.
Sotorasib is currently the only targeted drug approved to market for the treatment of locally advanced or metastatic NSCLC patients with KRASG12C mutations.
It has been awarded the title of orphan drug and breakthrough therapy and priority review qualification
.
According to a statistics on KRASG12C mutations in Chinese non-small cell lung cancer patients, KRAS mutations are the second most common genetic mutation in Chinese non-small cell lung cancer (NSCLC) patients
.
About 10% of NSCLC patients carry KRAS mutations, of which nearly 30% are KRASG12C mutation subtypes (KRASG12C mutation is a biomarker of poor prognosis for Chinese non-small cell lung cancer patients), that is, the occurrence of KRASG12C mutations in Chinese non-small cell lung cancer patients The rate is close to 3%[2]
.
Sotorasib's approval is mainly based on a phase I/II clinical trial (NCT03600883)
.
Clinical results showed that among 124 patients with locally advanced or metastatic NSCLC who had disease progression after receiving immune checkpoint inhibitors and/or platinum-based chemotherapy, the objective response rate (ORR) of the Sotorasib group reached 36%, and the median response continued The duration was 10 months, and 58% of patients had a duration of remission (DOR) ≥ 6 months [3]
.
For details of Sotorasib and the competitive landscape of KRAS inhibitor chemicals, see the picture below: (click to enlarge to view) You can also click the link below to get the corresponding PDF HD version: https://data.
pharmacodia.
com/v3/insight/#/ListPdf? tag=2Yaodu APP "points new gameplay" company enjoys the database of super-valued medicines intestinal-hepatic circulation in the human body: The influence of BCS classification on the solubility, permeability and dissolution of APIs May 2021 China CDE Drugs Click "Read the original text" for the declaration status to keep abreast of industry trends
